Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Journal of Translational Medicine
Published in: Journal of Translational Medicine 1/2011

Open Access 01-12-2011 | Research

Membranous expression of Her3 is associated with a decreased survival in head and neck squamous cell carcinoma

Authors: Mikiko Takikita, Ran Xie, Joon-Yong Chung, Hanbyoul Cho, Kris Ylaya, Seung-Mo Hong, Christopher A Moskaluk, Stephen M Hewitt

Published in: Journal of Translational Medicine | Issue 1/2011

Login to get access

Abstract

Background

Head and neck squamous cell carcinoma (HNSCC) still remains a lethal malignancy benefiting from the identification of the new target for early detection and/or development of new therapeutic regimens based on a better understanding of the biological mechanism for treatment. The overexpression of Her2 and Her3 receptors have been identified in various solid tumors, but its prognostic relevance in HNSCC remains controversial.

Methods

Three hundred eighty-seven primary HNSCCs, 20 matching metasis and 17 recurrent HNSCCs were arrayed into tissue microarrays. The relationships between Her2 and Her3 protein expression and clinicopathological parameters/survival of HNSCC patients were analyzed with immunohistochemistry.

Results

Her3 is detected as either a cytoplasmic or a membranous dominant expression pattern whereas Her2 expression showed uniform membranous form. In primary tumor tissues, high membranous Her2 expression level was found in 104 (26.9%) cases while positive membranous and cytoplasmic Her3 expression was observed in 34 (8.8%) and 300 (77.5%) samples, respectively. Membranous Her2 expression was significantly associated with histological grade (P = 0.021), as grade 2 tumors showed the highest positive expression. Membranous Her3 over-expression was significantly prevalent in metastatic tissues compared to primary tumors (P = 0.003). Survival analysis indicates that membranous Her3 expression is significantly associated with worse overall survival (P = 0.027) and is an independent prognostic factor in multivariate analysis (hazard ratio, 1.51; 95% confidence interval, 1.01-2.23; P = 0.040).

Conclusions

These results suggest that membranous Her3 expression is strongly associated with poor prognosis of patients with HNSCC and is a potential candidate molecule for targeted therapy.
Appendix
Available only for authorised users
Literature
1.
Society AC: Cancer Facts and Figures 2003. Atlanta, GA. 2003
2.
Forastiere A, Koch W, Trotti A, Sidransky D: Head and neck cancer. N Engl J Med. 2001, 345: 1890-1900. 10.1056/NEJMra001375.CrossRefPubMed
3.
Olayioye M, Neve R, Lane H, Hynes N: The ErbB signaling network: receptor heterodimerization in development and cancer. EMBO J. 2000, 19: 3159-3167. 10.1093/emboj/19.13.3159.PubMedCentralCrossRefPubMed
4.
Hynes N, Lane H: ERBB receptors and cancer: the complexity of targeted inhibitors. Nat Rev Cancer. 2005, 5: 341-354. 10.1038/nrc1609.CrossRefPubMed
5.
Schlessinger J: Common and distinct elements in cellular signaling via EGF and FGF receptors. Science. 2004, 306: 1506-1507. 10.1126/science.1105396.CrossRefPubMed
6.
Tzahar E, Waterman H, Chen X, Levkowitz G, Karunagaran D, Lavi S, Ratzkin B, Yarden Y: A hierarchical network of interreceptor interactions determines signal transduction by Neu differentiation factor/neuregulin and epidermal growth factor. Mol Cell Biol. 1996, 16: 5276-5287.PubMedCentralCrossRefPubMed
7.
Holbro T, Beerli RR, Maurer F, Koziczak M, Barbas CF, Hynes NE: The ErbB2/ErbB3 heterodimer functions as an oncogenic unit: ErbB2 requires ErbB3 to drive breast tumor cell proliferation. Proc Natl Acad Sci USA. 2003, 100: 8933-8938. 10.1073/pnas.1537685100.PubMedCentralCrossRefPubMed
8.
Adams G, Weiner L: Monoclonal antibody therapy of cancer. Nat Biotechnol. 2005, 23: 1147-1157. 10.1038/nbt1137.CrossRefPubMed
9.
Shawver L, Slamon D, Ullrich A: Smart drugs: tyrosine kinase inhibitors in cancer therapy. Cancer Cell. 2002, 1: 117-123. 10.1016/S1535-6108(02)00039-9.CrossRefPubMed
10.
Sergina N, Rausch M, Wang D, Blair J, Hann B, Shokat K, Moasser M: Escape from HER-family tyrosine kinase inhibitor therapy by the kinase-inactive HER3. Nature. 2007, 445: 437-441. 10.1038/nature05474.PubMedCentralCrossRefPubMed
11.
Cavalot A, Martone T, Roggero N, Brondino G, Pagano M, Cortesina G: Prognostic impact of HER-2/neu expression on squamous head and neck carcinomas. Head Neck. 2007, 29: 655-664. 10.1002/hed.20574.CrossRefPubMed
12.
Wei Q, Sheng L, Shui Y, Hu Q, Nordgren H, Carlsson J: EGFR, HER2, and HER3 expression in laryngeal primary tumors and corresponding metastases. Ann Surg Oncol. 2008, 15: 1193-1201. 10.1245/s10434-007-9771-3.CrossRefPubMed
13.
Ciardiello F, Tortora G: A novel approach in the treatment of cancer: targeting the epidermal growth factor receptor. Clin Cancer Res. 2001, 7: 2958-2970.PubMed
14.
Soulieres D, Senzer N, Vokes E, Hidalgo M, Agarwala S, Siu L: Multicenter phase II study of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent or metastatic squamous cell cancer of the head and neck. J Clin Oncol. 2004, 22: 77-85.CrossRefPubMed
15.
Crombet T, Osorio M, Cruz T, Roca C, del Castillo R, Mon R, Iznaga-Escobar N, Figueredo R, Koropatnick J, Renginfo E: Use of the humanized anti-epidermal growth factor receptor monoclonal antibody h-R3 in combination with radiotherapy in the treatment of locally advanced head and neck cancer patients. J Clin Oncol. 2004, 22: 1646-1654. 10.1200/JCO.2004.03.089.CrossRefPubMed
16.
Kononen J, Bubendorf L, Kallioniemi A, Bärlund M, Schraml P, Leighton S, Torhorst J, Mihatsch M, Sauter G, Kallioniemi O: Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nat Med. 1998, 4: 844-847. 10.1038/nm0798-844.CrossRefPubMed
17.
Jacobs TW, Gown AM, Yaziji H, Barnes MJ, Schnitt SJ: Specificity of HercepTest in determining HER-2/neu status of breast cancers using the United States Food and Drug Administration-approved scoring system. J Clin Oncol. 1999, 17: 1983-1987.PubMed
18.
Grunwald V, Hidalgo M: Developing inhibitors of the epidermal growth factor receptor for cancer treatment. J Natl Cancer Inst. 2003, 95: 851-867. 10.1093/jnci/95.12.851.CrossRefPubMed
19.
Ciardiello F, Tortora G: EGFR antagonists in cancer treatment. N Engl J Med. 2008, 358: 1160-1174. 10.1056/NEJMra0707704.CrossRefPubMed
20.
Hayes DF, Thor AD, Dressler LG, Weaver D, Edgerton S, Cowan D, Broadwater G, Goldstein LJ, Martino S, Ingle JN: HER2 and response to paclitaxel in node-positive breast cancer. N Engl J Med. 2007, 357: 1496-1506. 10.1056/NEJMoa071167.CrossRefPubMed
21.
Slamon DJ, Godolphin W, Jones LA, Holt JA, Wong SG, Keith DE, Levin WJ, Stuart SG, Udove J, Ullrich A: Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science. 1989, 244: 707-712. 10.1126/science.2470152.CrossRefPubMed
22.
Takehana T, Kunitomo K, Kono K, Kitahara F, Iizuka H, Matsumoto Y, Fujino MA, Ooi A: Status of c-erbB-2 in gastric adenocarcinoma: a comparative study of immunohistochemistry, fluorescence in situ hybridization and enzyme-linked immuno-sorbent assay. Int J Cancer. 2002, 98: 833-837. 10.1002/ijc.10257.CrossRefPubMed
23.
Osako T, Miyahara M, Uchino S, Inomata M, Kitano S, Kobayashi M: Immunohistochemical study of c-erbB-2 protein in colorectal cancer and the correlation with patient survival. Oncology. 1998, 55: 548-555. 10.1159/000011911.CrossRefPubMed
24.
D'Emilia J, Bulovas K, D'Ercole K, Wolf B, Steele G, Summerhayes IC: Expression of the c-erbB-2 gene product (p185) at different stages of neoplastic progression in the colon. Oncogene. 1989, 4: 1233-1239.PubMed
25.
Kearsley JH, Leonard JH, Walsh MD, Wright GR: A comparison of epidermal growth factor receptor (EGFR) and c-erbB-2 oncogene expression in head and neck squamous cell carcinomas. Pathology. 1991, 23: 189-194. 10.3109/00313029109063564.CrossRefPubMed
26.
Craven JM, Pavelic ZP, Stambrook PJ, Pavelic L, Gapany M, Kelley DJ, Gapany S, Gluckman JL: Expression of c-erbB-2 gene in human head and neck carcinoma. Anticancer Res. 1992, 12: 2273-2276.PubMed
27.
Field JK, Spandidos DA, Yiagnisis M, Gosney JR, Papadimitriou K, Stell PM: C-erbB-2 expression in squamous cell carcinoma of the head and neck. Anticancer Res. 1992, 12: 613-619.PubMed
28.
Ibrahim SO, Vasstrand EN, Liavaag PG, Johannessen AC, Lillehaug JR: Expression of c-erbB proto-oncogene family members in squamous cell carcinoma of the head and neck. Anticancer Res. 1997, 17: 4539-4546.PubMed
29.
Xia W, Lau YK, Zhang HZ, Xiao FY, Johnston DA, Liu AR, Li L, Katz RL, Hung MC: Combination of EGFR, HER-2/neu, and HER-3 is a stronger predictor for the outcome of oral squamous cell carcinoma than any individual family members. Clin Cancer Res. 1999, 5: 4164-4174.PubMed
30.
Giatromanolaki A, Koukourakis MI, Sivridis E, Fountzilas G: c-erbB-2 oncoprotein is overexpressed in poorly vascularised squamous cell carcinomas of the head and neck, but is not associated with response to cytotoxic therapy or survival. Anticancer Res. 2000, 20: 997-1004.PubMed
31.
Salesiotis AN, Cullen KJ: Molecular markers predictive of response and prognosis in the patient with advanced squamous cell carcinoma of the head and neck: evolution of a model beyond TNM staging. Curr Opin Oncol. 2000, 12: 229-239. 10.1097/00001622-200005000-00008.CrossRefPubMed
32.
Shiga H, Rasmussen AA, Johnston PG, Langmacher M, Baylor A, Lee M, Cullen KJ: Prognostic value of c-erbB2 and other markers in patients treated with chemotherapy for recurrent head and neck cancer. Head Neck. 2000, 22: 599-608. 10.1002/1097-0347(200009)22:6<599::AID-HED9>3.0.CO;2-M.CrossRefPubMed
33.
Werkmeister R, Brandt B, Joos U: Clinical relevance of erbB-1 and -2 oncogenes in oral carcinomas. Oral Oncol. 2000, 36: 100-105. 10.1016/S1368-8375(99)00069-X.CrossRefPubMed
34.
Hoffmann TK, Ballo H, Braunstein S, Van Lierop A, Wagenmann M, Bier H: Serum level and tissue expression of c-erbB-1 and c-erbB-2 proto-oncogene products in patients with squamous cell carcinoma of the head and neck. Oral Oncol. 2001, 37: 50-56. 10.1016/S1368-8375(00)00056-7.CrossRefPubMed
35.
Bang YJ, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A, Lordick F, Ohtsu A, Omuro Y, Satoh T: Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet. 376: 687-697.
36.
Gusterson BA, Gullick WJ, Venter DJ, Powles TJ, Elliott C, Ashley S, Tidy A, Harrison S: Immunohistochemical localization of c-erbB-2 in human breast carcinomas. Mol Cell Probes. 1987, 1: 383-391. 10.1016/0890-8508(87)90019-3.CrossRefPubMed
37.
Tzahar E, Waterman H, Chen X, Levkowitz G, Karunagaran D, Lavi S, Ratzkin BJ, Yarden Y: A hierarchical network of interreceptor interactions determines signal transduction by Neu differentiation factor/neuregulin and epidermal growth factor. Mol Cell Biol. 1996, 16: 5276-5287.PubMedCentralCrossRefPubMed
38.
Kapitanovic S, Radosevic S, Slade N, Kapitanovic M, Andelinovic S, Ferencic Z, Tavassoli M, Spaventi S, Pavelic K, Spaventi R: Expression of erbB-3 protein in colorectal adenocarcinoma: correlation with poor survival. J Cancer Res Clin Oncol. 2000, 126: 205-211. 10.1007/s004320050034.CrossRefPubMed
39.
Witton CJ, Reeves JR, Going JJ, Cooke TG, Bartlett JM: Expression of the HER1-4 family of receptor tyrosine kinases in breast cancer. J Pathol. 2003, 200: 290-297. 10.1002/path.1370.CrossRefPubMed
40.
Hayashi M, Inokuchi M, Takagi Y, Yamada H, Kojima K, Kumagai J, Kawano T, Sugihara K: High expression of HER3 is associated with a decreased survival in gastric cancer. Clin Cancer Res. 2008, 14: 7843-7849. 10.1158/1078-0432.CCR-08-1064.CrossRefPubMed
41.
Abd El-Rehim DM, Pinder SE, Paish CE, Bell JA, Rampaul RS, Blamey RW, Robertson JF, Nicholson RI, Ellis IO: Expression and co-expression of the members of the epidermal growth factor receptor (EGFR) family in invasive breast carcinoma. Br J Cancer. 2004, 91: 1532-1542. 10.1038/sj.bjc.6602184.PubMedCentralCrossRefPubMed
42.
Suo Z, Risberg B, Kalsson MG, Willman K, Tierens A, Skovlund E, Nesland JM: EGFR family expression in breast carcinomas. c-erbB-2 and c-erbB-4 receptors have different effects on survival. J Pathol. 2002, 196: 17-25. 10.1002/path.1003.CrossRefPubMed
43.
Sassen A, Rochon J, Wild P, Hartmann A, Hofstaedter F, Schwarz S, Brockhoff G: Cytogenetic analysis of HER1/EGFR, HER2, HER3 and HER4 in 278 breast cancer patients. Breast Cancer Res. 2008, 10: R2-10.1186/bcr1843.PubMedCentralCrossRefPubMed
44.
Aubele M, Auer G, Walch AK, Munro A, Atkinson MJ, Braselmann H, Fornander T, Bartlett JM: PTK (protein tyrosine kinase)-6 and HER2 and 4, but not HER1 and 3 predict long-term survival in breast carcinomas. Br J Cancer. 2007, 96: 801-807. 10.1038/sj.bjc.6603613.PubMedCentralCrossRefPubMed
45.
Fetsch PA, Abati A: The effects of antibody clone and pretreatment method on the results of HER2 immunostaining in cytologic samples of metastatic breast cancer: A query and a review of the literature. Diagn Cytopathol. 2007, 35: 319-328. 10.1002/dc.20638.CrossRefPubMed
46.
Wei Q, Chen L, Sheng L, Nordgren H, Wester K, Carlsson J: EGFR, HER2 and HER3 expression in esophageal primary tumours and corresponding metastases. Int J Oncol. 2007, 31: 493-499.PubMed
47.
Tanner B, Hasenclever D, Stern K, Schormann W, Bezler M, Hermes M, Brulport M, Bauer A, Schiffer I, Gebhard S: ErbB-3 predicts survival in ovarian cancer. J Clin Oncol. 2006, 24: 4317-4323. 10.1200/JCO.2005.04.8397.CrossRefPubMed
48.
Kountourakis P, Pavlakis K, Psyrri A, Rontogianni D, Xiros N, Patsouris E, Pectasides D, Economopoulos T: Prognostic significance of HER3 and HER4 protein expression in colorectal adenocarcinomas. BMC Cancer. 2006, 6: 46-10.1186/1471-2407-6-46.PubMedCentralCrossRefPubMed
Metadata
Title
Membranous expression of Her3 is associated with a decreased survival in head and neck squamous cell carcinoma
Authors
Mikiko Takikita
Ran Xie
Joon-Yong Chung
Hanbyoul Cho
Kris Ylaya
Seung-Mo Hong
Christopher A Moskaluk
Stephen M Hewitt
Publication date
01-12-2011
Publisher
BioMed Central
Published in
Journal of Translational Medicine / Issue 1/2011
Electronic ISSN: 1479-5876
DOI
https://doi.org/10.1186/1479-5876-9-126

Other articles of this Issue 1/2011

Journal of Translational Medicine 1/2011 Go to the issue

Research

Electroporation increases antitumoral efficacy of the bcl-2 antisense G3139 and chemotherapy in a human melanoma xenograft

Research

Cytotoxic T lymphocyte responses against melanocytes and melanoma

Research

MiRNA-205 modulates cellular invasion and migration via regulating zinc finger E-box binding homeobox 2 expression in esophageal squamous cell carcinoma cells

Research

A predicted protein, KIAA0247, is a cell cycle modulator in colorectal cancer cells under 5-FU treatment

Research

Combination of cyclosporine and erythropoietin improves brain infarct size and neurological function in rats after ischemic stroke

Research

A novel patient-derived intra-femoral xenograft model of bone metastatic prostate cancer that recapitulates mixed osteolytic and osteoblastic lesions
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits